Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience

Petrioli, Roberto; Roviello, Giandomenico; Laera, Letizia; Luzzi, Luca; Paladini, Piero; Ghiribelli, Claudia; Voltolini, Luca; Martellucci, Ignazio; Bianco, Vincenzo; Francini, Edoardo

doi:10.1016/j.cllc.2015.05.005

Cited by 17 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, the drugs used in combination should possess the following features: to use drugs with nonoverlapping toxicities so that each drug can be administered at near-maximal dose; combine agents with different mechanisms of action and minimal cross-resistance in order to inhibit the emergence of broad spectrum drug resistance; preferentially use drugs with proven activity as single drugs and administer the combination at early stage disease and at a schedule with a minimal treatment-free period between cycles but still allowing the recovery of sensitive target tissues (26,27). Nowadays, drugs combination studies for cancer therapy have been tried by many researchers (24,(28)(29)(30). Combinations of topo I inhibitor camptothecin and topo II inhibitor doxorubicin have been found to synergistically inhibit cancer cell growth in vitro (28).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes

Oksuzoglu¹,

Tırınoğlu²,

Kerimoğlu³

2016

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Combinations of topo I inhibitor camptothecin and topo II inhibitor doxorubicin have been found to synergistically inhibit cancer cell growth in vitro (28). Etoposide and cisplatin is the most used combination chemotherapy regimen in extensive-stage disease small-cell lung cancer and usually achieves a high initial response rate (29).…”

Section: Discussionmentioning

confidence: 99%

The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes

Oksuzoglu¹,

Tırınoğlu²,

Kerimoğlu³

2016

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…The dose of bevacizumab administered for the IFCT-0802 study was 7.5 mg/kg, not the routine dose of 15 mg/kg. A single-institution experience showed that cisplatin–etoposide (EP) combined with bevacizumab before oral etoposide administration and bevacizumab maintenance therapy shows likely more efficacy and is relatively safe in extensive-stage SCLC patients 11. Another randomized phase II study of the addition of bevacizumab to cisplatin or carboplatin plus etoposide (EC) for the treatment of extensive-stage SCLC achieved the similar results which only improved PFS but not OS with an acceptable toxicity profile 12.…”

Section: Bevacizumabmentioning

confidence: 99%

Advances in antiangiogenic treatment of small-cell lung cancer

Lu¹,

Jiang²

2017

OTT

View full text Add to dashboard Cite

Small-cell lung cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid growth rate, strong aggressiveness, early metastases, and poor prognosis. Angiogenesis greatly contributes to the metastatic process of SCLC, which has a higher vascularization compared with non-small-cell lung cancer (NSCLC). SCLC might constitute an ideal malignancy for assessing new antiangiogenic drugs and therapeutic strategies. Combining bevacizumab with paclitaxel has therapeutic benefits in chemoresistant, relapsed SCLC. The cisplatin–etoposide and bevacizumab combination, as the first-line treatment for extensive-stage SCLC, can improve progression-free survival (PFS), with an acceptable toxicity profile. Ziv-aflibercept combined with topotecan is promising for platinum-refractory SCLC. Chemotherapy combined with thalidomide cannot prolong survival. Maintenance sunitinib of 37.5 mg/day in extensive-stage SCLC patients following induction chemotherapy with platinum/etoposide improves median PFS by 1.6 months. Serum angiopoietin-2 concentrations and vascular endothelial growth factor levels correlate with poor prognosis. Bevacizumab, ziv-aflibercept, and sunitinib are worthy of further evaluation. Thalidomide, sorafenib, pomalidomide, and cediranib may not be suitable for SCLC.

show abstract

“…Additionally, SCLC histology is very heterogeneous in terms of somatic mutations, but targeted treatment approaches have had limited success in SCLC in clinical trials and its role is unclear. 85 , 86 Furthermore, the incidences of EGFR mutations and ALK translocation in high-grade pulmonary neuroendocrine carcinomas (SCLC and large-cell neuroendocrine carcinoma) are very low. Therefore, according to the International Association for the Study of Lung Cancer (IASLC), ALK and EGFR testing are recommended for adenocarcinomas and mixed lung cancers with an adenocarcinoma component.…”

Section: Detection Of Egfr Mutations and Alk Rearrangementmentioning

confidence: 99%

The distinctive nature of adenocarcinoma of the lung

Roviello

2015

OTT

Self Cite

View full text Add to dashboard Cite

In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors directed against the echinoderm microtubule-like protein 4-anaplastic lymphoma kinase translocation. The possibility of these new molecules being used to treat patients without adenocarcinoma histology is notably small. For example, EGFR mutations and anaplastic lymphoma kinase fusion gene rearrangement are rare in patients with squamous cell carcinoma (generally <1%). Additionally, the benefit of targeted treatment approaches in patients with small-cell lung cancer histology is limited. All of these findings highlight the distinctive nature of adenocarcinoma of the lung among all lung cancer subtypes. Unfortunately, to date, less than 15% of patients with adenocarcinoma of the lung are ideal candidates for these targeted therapies.

show abstract

Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience

Cited by 17 publications

References 35 publications

The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes

The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes

Advances in antiangiogenic treatment of small-cell lung cancer

The distinctive nature of adenocarcinoma of the lung

Contact Info

Product

Resources

About